We are committed to developing safe and effective vaccines against infectious diseases that address important unmet medical needs to save lives and improve health. We were founded on breakthrough computationally-designed virus-like particle technology, developed at the Institute for Protein Design and exclusively licensed for a variety of infectious disease indications from the University of Washington.
We believe that science and technology can and will continue to improve public health and that preventing infection is preferable to treating illness.
With a strong investor syndicate providing both significant expertise and financial support, we are focused on advancing our RSV, hMPV, and SARS-CoV-2 vaccine candidates into the clinic.
Our team has extensive experience in leading successful vaccine development and creating commercially valuable products from innovative, breakthrough technologies.